溶解性 | Soluble in ethanol (~20 mg/ml), DMSO (25 mg/ml), DMF (~20 mg/ml), and water (<1 mg/ml). |
存贮条件 | 储存温度 2-8°C |
应用 | An immunomodulatory CB1 receptor inverse agonist. |
产品介绍 | Rimonabant是一个大脑中心大麻素受体(CB1)特异性口服拮抗剂。在hCB1转染HEK293细胞中IC50浓度为13.6 nM,EC50浓度为17.3 nM。 |
备注 | Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane. |
生化机理 | Rimonabant, also known as SR141716, was the first selective CB1 (cannabinoid 1) central receptor inverse agonist (Ki = 1.8 nM). It is widely used as a tool to investigate CB receptor properties and the mechanisms by which CB agonists exert their pharmacological effects. In rodent models and clinical trials, rimonabant effectively induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios. However, rimonabant reportedly produces adverse psychiatric and neurological effects (e.g., depression or anxiety) and therefore is not approved by the FDA for use as a weight control medication. Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro. |
别名 | 利莫那班; 5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-N-(1-哌啶基)-1H-吡唑-3-甲酰胺;SR 141716;SR141716;SR-141716; 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide |
利莫那班
Rimonabant (订货以英文为准)
编号:R125003
CAS号:168273-06-1
分子式:C22H21N4OCL3
分子量:463.79
产品名称 | Rimonabant |
中文名称 | 利莫那班 |
CAS号 | 168273-06-1 |
分子式(M.F.) | C22H21N4OCL3 |
分子量(M.W.) | 463.79 |
储存条件 | 2-8°C储存 |
标识符号 | https://www.aladdin-e.com/images/ghs/ghs02.jpg,https://www.aladdin-e.com/images/ghs/ghs06.jpg,https://www.aladdin-e.com/images/ghs/ghs08.jpg |
信号词 | Danger |
危害声明 | H225-H301 + H311 + H331-H370 |
警示性声明 | P210-P260-P280-P301 + P310-P311 |
WGK德国 | 1 |
闪点(摄氏) | 48.2 °F |
搜索质检报告(COA)
搜索MSDS
相关产品